So is adaptive HTA, which is a “second-best” approach to locally informed and conducted HTA even in the best of circumstances, the only option available for MICs without a fully-funded process? We think there’s another possibility—virtual HTA.
CGD Policy Blogs
Rapid Priority Setting in Low- and Middle-Income Countries: The Potential of Adaptive Health Technology Assessments
Health budgets are limited and decision makers in all countries face very challenging decisions about which health interventions will be provided, and which will not. COVID has only added to this pressing priority setting problem. In this blog, we highlight key takeaways from our recent commentary in the BMJ Global Health, where we make the case for “adaptive health technology assessment,” or “aHTA.”
In 2020, epidemiological modelling went from relative obscurity to being central in helping governments, and the public, understand COVID-19 as it spread around the world. In 2021, with the emergence of effective COVID-19 vaccines, Health Technology Assessment (HTA) will be critical to making the best possible decisions in bringing the pandemic under control, particularly in low-and middle-income countries (LMICs). In this blog we look at the potential of HTA to inform how much vaccine countries should buy, who should pay, and how vaccines can be most effectively delivered.
In the wake of the COVID-19 crisis, many sub-Saharan African countries will face serious economic crises and shrinking public spending. If countries are unable to spend more, they need to spend better. Europe has leading expertise in building institutions for priority-setting in health, making it an obvious potential source for collaboration with the Global South.
To attain and sustain universal health coverage, we must harness the power of healthcare innovation. But how can we do so when in many settings, these innovations do not align with local priorities?
With a focus on tests, treatments, and a vaccine, we take a look at the emerging global clinical and economic evidence-base underpinning some of these technologies, the mechanisms (mostly global) for financing these commodities, and, finally, the decision-making processes for selecting technologies. This includes identifying the right subpopulations and negotiating a cost-effective tiered price across countries and regions.
As the COVID-19 pandemic continues to unfold, it has become increasingly accepted that day-to-day life will not return to anything close to normality until a vaccine or effective treatment is available and widely accessible.
Does Cancer Treatment Warrant Special Consideration from Health Decision-Makers in Low- and Middle-Income Countries?
As the international community grapples with COVID-19 and the extent to which countries should fund outbreak preparedness, governments also continue to face day-to-day healthcare funding decisions, including for cancer treatments. As policymakers increasingly take cancer seriously, and allocate a greater proportion of their health expenditure to its treatment, we ask whether cancer treatment is the most cost-effective way for health ministers to spend their money.
With a number of African countries confirming their first cases of COVID-19 and the continent bracing for major outbreaks, health system resilience and basic functionality emerge once again as the determining factor for a successful response.
Governments are under continuous pressure to make difficult trade-offs about the use of scarce public resources. This applies to the budget as a whole, but also within sectors like health.